Secondary Logo

Journal Logo

March 2018 - Volume 33 - Issue 2
pp: 59-119

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union

Brody, Robert S.; Liss, Charles L.; Wray, Heather; More

International Clinical Psychopharmacology. 33(2):59-65, March 2018.

Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial

Morabbi, Mohammad-Javad; Razaghi, Emran; Moazen-Zadeh, Ehsan; More

International Clinical Psychopharmacology. 33(2):111-119, March 2018.